Refine
Language
- English (3)
Has Fulltext
- yes (3)
Is part of the Bibliography
- no (3)
Keywords
- 4-Methoxyzimtaldehyd (1)
- 4-methoxycinnamaldehyde (MCA) (1)
- Diabrotica virgifera virgifera (1)
- Zea mays (1)
- diversion technique (1)
- kairomone (1)
Institute
- Medizin (2)
Mapping cortical brain asymmetry in 17,141 healthy individuals worldwide via the ENIGMA Consortium
(2017)
The leaf beetle Diabrotica virgifera virgifera (Coleoptera: Chrysomelidae), (D.v.v.), also called the western corn rootworm, is endemic to the New World and ranks among the top ten insect pests in worldwide grain production. D.v.v. causes annual damages of 1 billion US Dollars and is a notoriously difficult insect pest to control and manage, as entomological history of the past 50 years amply demonstrates (METCALF 1986). Considering recent emphasis on environmentally compatible and sustainable management strategies, entomologists and practitioners are encouraged to pay increased attention to novel approaches such as biotechnial methods which today are characterized by preferential use of signal compounds. Fortunately, both insect and plants provide a wide variety of such natural resources. In the case of D.v.v., sex pheromonesand plant kairomones as specific attractants and management tools are relatively well investigated through numerous contributions by GUSS et al. (1982), METCALF & METCALF (1992), METCALF (1994) and many recent publications on the advance and spread of D.v.v. within Europe (BERGER 1995-2004, HUMMEL 2003). Principle of MSD method: In this paper, the plant kairomone 4-methoxycinnamaldehyde (MCA), a specific attractant for D.v.v., is being used as a tool within the newly proposed "MSD" strategy. It combines a two pronge approach consisting as the well known mass trapping with the novel shielding and deflecting, called in short "diversion" and introduced here for the first time. An invisible “curtain” or “fence” of MCA vapor released from a MCA trap line establishes a behavioral barrier which the flying beetles cannot easily pass without being 1. either caught in one of the high capacity traps or 2. being diverted elsewhere. The net effect is a significant reduction in adult population density and oviposition within the MCA treated field as compared to an untreated control field. These effects can be experimentally measured by 1. adult beetle counts on maize plants, 2. by counts in independent monitoring traps baited with the D.v.v. sex pheromone, and 3. by egg counts taken in soil samples.
Introduction: Acute kidney injury (AKI) can evolve quickly and clinical measures of function often fail to detect AKI at a time when interventions are likely to provide benefit. Identifying early markers of kidney damage has been difficult due to the complex nature of human AKI, in which multiple etiologies exist. The objective of this study was to identify and validate novel biomarkers of AKI.
Methods: We performed two multicenter observational studies in critically ill patients at risk for AKI - discovery and validation. The top two markers from discovery were validated in a second study (Sapphire) and compared to a number of previously described biomarkers. In the discovery phase, we enrolled 522 adults in three distinct cohorts including patients with sepsis, shock, major surgery, and trauma and examined over 300 markers. In the Sapphire validation study, we enrolled 744 adult subjects with critical illness and without evidence of AKI at enrollment; the final analysis cohort was a heterogeneous sample of 728 critically ill patients. The primary endpoint was moderate to severe AKI (KDIGO stage 2 to 3) within 12 hours of sample collection.
Results: Moderate to severe AKI occurred in 14% of Sapphire subjects. The two top biomarkers from discovery were validated. Urine insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2), both inducers of G1 cell cycle arrest, a key mechanism implicated in AKI, together demonstrated an AUC of 0.80 (0.76 and 0.79 alone). Urine [TIMP-2].[IGFBP7] was significantly superior to all previously described markers of AKI (P <0.002), none of which achieved an AUC >0.72. Furthermore, [TIMP-2].[IGFBP7] significantly improved risk stratification when added to a nine-variable clinical model when analyzed using Cox proportional hazards model, generalized estimating equation, integrated discrimination improvement or net reclassification improvement. Finally, in sensitivity analyses [TIMP-2].[IGFBP7] remained significant and superior to all other markers regardless of changes in reference creatinine method.
Conclusions: Two novel markers for AKI have been identified and validated in independent multicenter cohorts. Both markers are superior to existing markers, provide additional information over clinical variables and add mechanistic insight into AKI. Trial registration: ClinicalTrials.gov number NCT01209169.